After a successful interim review, the Else Kröner-Fresenius-Foundation is now funding a second term of our Tübingen Training Network on the topic of "Therapy Resistance of Solid Tumors"…
A team led by Prof. Philipp Kahle discovers a basic disease mechanism of amyotrophic lateral sclerosis (ALS). Their finding: a red wine substance regulates an important enzyme and could be a…
The research group aims to uncover mechanisms of action of deep brain stimulation (DBS) therapy and to translate the pathophysiological insights into future developments. Currently, Parkinson’s…
At the HIH, as part of the Johannes Dichgans scholarship program, doctoral scholarships for students of human medicine will again be offered for the winter semester 2022/23.
May 10 marks Tag gegen den Schlaganfall in Germany. In an interview with the Hertie Foundation on this occasion, Dr. Sven Poli explains high-dose oxygen therapy, which is intended to prevent…
The Hertie Institute for Clinical Brain Research will receive permanent funding from the State of Baden-Württemberg in the future. The institute celebrated its 20th anniversary on Wednesday, May 4,…
Since April, the Tumor Center CCC Tübingen-Stuttgart has been headed by Prof. Sara Brucker (Department of Women's Health Tübingen). Prof. Ghazaleh Tabatabai became deputy spokesperson of the clinical…
The Hertie Institute for Clinical Brain Research (HIH) as part of the Center of Neurology of the University of Tübingen has been chosen by The Michael J. Fox Foundation for Parkinson’s Research…
Bringing basic scientists and clinical researchers closer together and promoting their exchange of knowledge and expertise: These are the goals of the research network and junior researcher support…
